Patient reported outcomes in systemic vasculitis

Purpose of review: This review paper evaluates the use of patient reported outcome (PROs) in systemic vasculitis and the increasing incorporation of these measures in the evaluation of clinical outcomes and healthcare provision. Recent findings: Generic PROs such as the SF-12, SF-36, EQ-5D have been used to evaluate health-related quality of life (HRQOL) across the spectrum of vasculitis; including giant cell arteritis, antineutrophil cytoplasmic antibody (ANCA)-related vasculitis and immunoglobulin A vasculitis (IgA) vasculitis. More recently disease-specific PROs have been developed including the associated vasculitis (AAV)-PRO and GCA-PRO, whilst further work is ongoing including a Steroid-PRO. Summary: Generic and disease-specific PROs are complimentary in nature, but the advent of disease-specific PROs allows evaluation of the impact of specific symptoms and intervention on patient HRQOL. Following the COVID-19 pandemic, the advent of increasing virtual work has brought the potential for electronic-PRO measures to the forefront and is a current area of interest.

Citation

Crawshaw, H., Wells, M., Austin, K., Janagan, S., & Robson, J. C. (2022). Patient reported outcomes in systemic vasculitis. Current opinion in rheumatology, 34(1), 33–38. https://doi.org/10.1097/BOR.0000000000000850

DOI

10.1097/BOR.0000000000000850

URI

https://hdl.handle.net/20.500.14709/555